Literature DB >> 620483

Pharmacokinetics of warfarin enantiomers: a search for intrasubject correlations.

L B Wingard, R A O'Reilly, G Levy.   

Abstract

The total body clearance of single doses of R(+)-, S(-)-, and racemic warfarin and the plasma concentration-anticoagulant effect curves for these drugs were determined in 10 healthy men, 21 to 51 yr old. This information was used to calculate the steady-state dose required to decrease prothrombin complex activity to about 30% of normal. This dose (mean +/- SD in mg/70 kg/day) is 17.8 +/- 9.3 for R(+)-warfarin, 6.63 +/- 2.19 for S(-)-warfarin, and 9.4 +/- 1.7 for racemic warfarin. There is a correlation between the maintenance doses of racemic and S(-)-warfarin (r = 0.89, p less than 0.01) but not between those of racemic and R(+)-warfarin (r = 0.30, NS). According to these calculations, the maintenance dose of racemic warfarin required by an individual patient may be a useful predictor of maintenance dose of S(-)-warfarin which will produce a comparable degree of anticoagulation. No such predictability is evident with respect to R(+)-warfarin. The slopes of the log plasma concentration-anticoagulant effect curves for R(+)-and S(-)-warfarin differ significantly. Therefore, the potency ratio of these enantiomers is dose-and concentration-dependent.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 620483     DOI: 10.1002/cpt1978232212

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  14 in total

Review 1.  Clinical relevance of cimetidine drug interactions.

Authors:  A F Shinn
Journal:  Drug Saf       Date:  1992 Jul-Aug       Impact factor: 5.606

Review 2.  Stereoselectivity in clinical pharmacokinetics and drug development.

Authors:  D B Campbell
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Apr-Jun       Impact factor: 2.441

Review 3.  The use of kinetic-dynamic interactions in the evaluation of drugs.

Authors:  D B Campbell
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

4.  Enantiomers of warfarin and vitamin K1 metabolism.

Authors:  I A Choonara; B P Haynes; S Cholerton; A M Breckenridge; B K Park
Journal:  Br J Clin Pharmacol       Date:  1986-12       Impact factor: 4.335

Review 5.  Importance of drug enantiomers in clinical pharmacology.

Authors:  K Williams; E Lee
Journal:  Drugs       Date:  1985-10       Impact factor: 9.546

6.  Drug interactions with warfarin enantiomers--a different perspective.

Authors:  L B Wingard; G Levy
Journal:  Br J Clin Pharmacol       Date:  1978-11       Impact factor: 4.335

7.  A study of the relationship between the pharmacokinetics and the pharmacodynamics of the 4-hydroxycoumarin anticoagulants warfarin, difenacoum and brodifacoum in the rabbit.

Authors:  A M Breckenridge; S Cholerton; J A Hart; B K Park; A K Scott
Journal:  Br J Pharmacol       Date:  1985-01       Impact factor: 8.739

Review 8.  Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship.

Authors:  N H Holford
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

9.  High clearance of (S)-warfarin in a warfarin-resistant subject.

Authors:  H O Hallak; P J Wedlund; M W Modi; I H Patel; G L Lewis; B Woodruff; A A Trowbridge
Journal:  Br J Clin Pharmacol       Date:  1993-03       Impact factor: 4.335

10.  Stereoselective interaction between the R enantiomer of warfarin and cimetidine.

Authors:  I A Choonara; S Cholerton; B P Haynes; A M Breckenridge; B K Park
Journal:  Br J Clin Pharmacol       Date:  1986-03       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.